

L1 1 S US 20070185096/PN

L2 FILE 'REGISTRY' ENTERED AT 14:29:42 ON 07 DEC 2009
L2 1 S 865470-96-8/RN
L2 SET NOTICE 1 DISPLAY
L2 SET NOTICE LOGIN DISPLAY

L3 FILE 'REGISTRY' ENTERED AT 14:30:06 ON 07 DEC 2009
L3 1 S 865470-97-9/RN
L3 SET NOTICE 1 DISPLAY
L3 SET NOTICE LOGIN DISPLAY

L4 FILE 'REGISTRY' ENTERED AT 14:30:20 ON 07 DEC 2009
L4 1 S 865470-98-0/RN
L4 SET NOTICE 1 DISPLAY
L4 SET NOTICE LOGIN DISPLAY

L5 FILE 'REGISTRY' ENTERED AT 14:30:34 ON 07 DEC 2009
L5 1 S 865470-99-1/RN
L5 SET NOTICE 1 DISPLAY
L5 SET NOTICE LOGIN DISPLAY

L6 FILE 'REGISTRY' ENTERED AT 14:30:49 ON 07 DEC 2009
L6 1 S 865471-00-7/RN
L6 SET NOTICE 1 DISPLAY
L6 SET NOTICE LOGIN DISPLAY

L7 FILE 'REGISTRY' ENTERED AT 14:31:07 ON 07 DEC 2009
L7 1 S 865471-01-8/RN
L7 SET NOTICE 1 DISPLAY
L7 SET NOTICE LOGIN DISPLAY

L8 FILE 'REGISTRY' ENTERED AT 14:31:28 ON 07 DEC 2009
L8 1 S 689141-48-8/RN
L8 SET NOTICE 1 DISPLAY
L8 SET NOTICE LOGIN DISPLAY

L9 FILE 'REGISTRY' ENTERED AT 14:31:49 ON 07 DEC 2009
L9 1 S 865470-74-2/RN
L9 SET NOTICE 1 DISPLAY
L9 SET NOTICE LOGIN DISPLAY

L10 FILE 'REGISTRY' ENTERED AT 14:32:09 ON 07 DEC 2009
L10 1 S 865470-85-5/RN
L10 SET NOTICE 1 DISPLAY
L10 SET NOTICE LOGIN DISPLAY

L11 FILE 'REGISTRY' ENTERED AT 14:35:21 ON 07 DEC 2009
L11 STRUCTURE uploaded
L12 39 S L11 SSS SAM
L13 762 S L11 SSS FULL

L14 FILE 'REGISTRY' ENTERED AT 14:39:17 ON 07 DEC 2009
L14 1 S 865471-04-1/RN
L14 SET NOTICE 1 DISPLAY
L14 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:39:41 ON 07 DEC 2009
L15 1 S 406940-52-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:40:15 ON 07 DEC 2009
L16 1 S 406941-75-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:41:18 ON 07 DEC 2009
L17 1 S 406942-68-5/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:41:54 ON 07 DEC 2009
L18 1 S 406943-07-5/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:42:23 ON 07 DEC 2009
L19 1 S 406944-37-4/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:42:48 ON 07 DEC 2009
L20 1 S 543700-68-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:43:14 ON 07 DEC 2009
L21 1 S 682754-93-4/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:43:32 ON 07 DEC 2009
L22 1 S 682755-55-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:43:51 ON 07 DEC 2009
L23 1 S 682755-63-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:44:09 ON 07 DEC 2009
L24 1 S 682755-73-3/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:52:59 ON 07 DEC 2009
L25 STRUCTURE UPLOADED
L26 0 S L25 SSS SAM
L27 0 S L25 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:53:38 ON 07 DEC 2009
L28 1 S US 20070185096/PN

FILE 'REGISTRY' ENTERED AT 14:53:58 ON 07 DEC 2009
L29 1 S 865470-94-6/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:54:10 ON 07 DEC 2009
L30 1 S 865471-20-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:54:23 ON 07 DEC 2009
L31 1 S 865471-17-6/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:54:38 ON 07 DEC 2009
L32 1 S 115029-23-7/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:54:56 ON 07 DEC 2009
L33 1 S 865471-01-8/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:55:14 ON 07 DEC 2009
L34 1 S 865471-02-9/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:55:31 ON 07 DEC 2009
L35 1 S 865471-03-0/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:55:51 ON 07 DEC 2009
L36 1 S 865471-04-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:56:08 ON 07 DEC 2009
L37 1 S 865471-05-2/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:56:27 ON 07 DEC 2009
L38 1 S 865471-06-3/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:56:47 ON 07 DEC 2009
L39 1 S 865471-08-5/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:57:08 ON 07 DEC 2009

L40 1 S 865471-10-9/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:57:30 ON 07 DEC 2009
L41 1 S 865471-12-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:58:07 ON 07 DEC 2009
L42 1 S 1019852-79-9/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:58:33 ON 07 DEC 2009
L43 1 S 689141-85-3/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:58:57 ON 07 DEC 2009
L44 1 S 400750-49-4/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:59:26 ON 07 DEC 2009
L45 1 S 682754-93-4/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:00:00 ON 07 DEC 2009
L46 1 S 682755-55-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:00:31 ON 07 DEC 2009
L47 1 S 682755-63-1/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:00:57 ON 07 DEC 2009
L48 1 S 682755-73-3/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:01:30 ON 07 DEC 2009
L49 1 S 682755-77-7/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:01:48 ON 07 DEC 2009
L50 1 S 865724-48-7/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:03:44 ON 07 DEC 2009
L51 1 S 865724-49-8/RN
 SET NOTICE 1 DISPLAY

SET NOTICE LOGIN DISPLAY

L52 FILE 'REGISTRY' ENTERED AT 15:04:09 ON 07 DEC 2009
1 S 865788-63-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L53 FILE 'REGISTRY' ENTERED AT 15:04:31 ON 07 DEC 2009
1 S 317846-22-3/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L54 FILE 'REGISTRY' ENTERED AT 15:05:01 ON 07 DEC 2009
1 S 301353-36-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L55 FILE 'REGISTRY' ENTERED AT 15:05:56 ON 07 DEC 2009
1 S 865470-74-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L56 FILE 'REGISTRY' ENTERED AT 15:06:27 ON 07 DEC 2009
1 S 865471-21-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L57 FILE 'REGISTRY' ENTERED AT 15:07:13 ON 07 DEC 2009
1 S 865475-79-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L58 FILE 'REGISTRY' ENTERED AT 15:07:37 ON 07 DEC 2009
1 S 865475-45-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L59 FILE 'REGISTRY' ENTERED AT 15:07:54 ON 07 DEC 2009
1 S 865471-65-4/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

L60 FILE 'REGISTRY' ENTERED AT 15:08:26 ON 07 DEC 2009
E 865471-48-7/RN
E 865724-48-7/RN
1 S E3
SET EXPAND CONTINUOUS

L61 FILE 'HCAPLUS' ENTERED AT 15:09:12 ON 07 DEC 2009
2 S L60
L62 3 S L59
L63 0 S L62 AND (PY<2004 OR AY<2004 OR PRY<2004)


L1 STRUCTURE uploaded

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,S

G3 Cy,Ak

L2 50 S L1 SSS SAM

L3 1054 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:58:01 ON 07 DEC 2009

L4 52 S L3


L5 21 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

L6 8 S L5 AND (SYNCYTIAL?)


L6 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of 2-(heterocyclimethyl)benzimidazoles as respiratory syncytial virus antiviral agents

GI



I



II


AB Title compds. I [wherein R1 = (CRaRb)nX; R2 = H; R3 = CONRhRi, CO2Rd, or (un)substituted alkyl; R4 = NH2, CONRhRi, heteroaryl, alkenyl, CO2Rd, N=CPH2, C(NOH)NH2, C(NH)NH2, or (un)substituted alkyl; R5 = CO2Rj or (un)substituted alkyl or alkenyl; Q = (un)substituted benzimidazolyl, benzotriazolyl, imidazopyridinyl, quinolinyl, quinazolinyl, benzyloxy, etc.; X = H or (un)substituted alkyl; Ra and Rb = independently H or (halo)alkyl; Rd = alkyl; Rh and Ri = independently H or alkyl; Rj = H or alkyl; n = 1-6; and pharmaceutically acceptable salts thereof] were prepared as antiviral compds. More particularly, the invention provides 2-(heterocyclimethyl)benzimidazole derivs. for the

treatment of respiratory syncytial virus (RSV) infection. For example, 1-isopropyl-1,3-dihydrobenzimidazol-2-one was coupled with 2-chloromethyl-1-(3-methylbutyl)-1H-benzimidazole-5-carbonitrile in the presence of Cs₂CO₃ in DMF to give II (95%). Disclosed compds. protected HEp-2 cells from RSV-induced cytopathic effects with EC₅₀ values between 50 µM and 0.001 µM, compared to an EC₅₀ of 3 µM for ribavirin. I also displayed antiviral activity by reducing viral protein expression in HEp-2 cells with EC₅₀ values between 50 µM and 0.001 µM, compared to an EC₅₀ value of 3 µM for ribavirin. Thus, I and compns. comprising I are useful for the treatment of RSV infections.

ACCESSION NUMBER: 2003:511082 HCAPLUS [Full-text](#)
DOCUMENT NUMBER: 139:85343
TITLE: Preparation of 2-(heterocyclimethyl)benzimidazoles as respiratory syncytial virus antiviral agents
INVENTOR(S): Yu, Kuo-long; Wang, Xiangdong; Sun, Yaxiong; Cianci, Christopher; Thuring, Jan Willem; Combrink, Keith; Meanwell, Nicholas; Zhang, Yi; Civiello, Rita L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2003053344	A2	20030703	WO 2002-US39220	
20021206 <-- WO 2003053344	A3	20031113		
CH, CN, GE, GH, LK, LR, OM, PH, TT, TZ,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
AZ, BY, EE, ES, BF, BJ,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

L6 ANSWER 8 OF 8 HCPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of benzimidazoles as respiratory syncytial virus
replication inhibitors.
GI




AB Title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH,
N:CHCH:CH, CH:NCH:CH; CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1,
R2R4NCOAX1, specified (substituted) (hetero)cycles; A =
(substituted) alkylene; X1 = imino, S, SO, SO2, O, CH2, CO,
CH(OH), etc.; R1 = (substituted) bicyclic heterocycle; G = bond,
(substituted) alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl,
piperidinyl, homopiperidinyl, etc.; R4 = H, alkyl, aralkyl], were
prepared. Thus, 1-[4-[(1-(2-quinolylmethyl)-1H-benzimidazol-2-
yl)amino]-1-piperidinyl]-3-methyl-2-butanone was hydrogenated
with PhCH2NH2 in MeOH over Pd/C to give N-[1-(2-amino-3-
methylbutyl)-4-piperidinyl]-1-(2-quinolylmethyl)-1H-benzimidazol-
2-amine and N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-
[(1,2,3,4-tetrahydro-2-quinolyl)methyl]-1H-benzimidazol-2-amine
tetrahydrochloride. Tested I inhibited respiratory syncytial
virus replication with IC50 = 0.0004-1.5849 μM.

ACCESSION NUMBER: 2001:12448 HCPLUS [Full-text](#)
DOCUMENT NUMBER: 134:86251
TITLE: Preparation of benzimidazoles as respiratory
syncytial virus replication inhibitors.
INVENTOR(S): Janssens, Frans Eduard; Lacrampe, Jean Fernand
Armand;
Gaston;
Guillemont, Jerome Emile Georges; Venet, Marc
PATENT ASSIGNEE(S): Andries, Koenraad Jozef Lodewijk Marcel
Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2001000615 20000620 <--	A1	20010104	WO 2000-EP5677	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, HR, HU,	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,			

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE,
 CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
 BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L6 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of imidazopyridine and imidazopyrimidine antiviral
 agents
 GI



AB The title compds. [I; W = O, S; R1 = (CR'R'')nX; X = H, alkyl, cycloalkyl, etc.; n = 2-6; R2 = H, alkyl, cycloalkyl, etc.; R3-R6 = H, halo, alkyl, etc.; A, B, E, D = CH, CQ, N, NO; provided at least one of A, B, E or D is not CH or CQ; Q = halo, alkyl, alkyl substituted with 1-3 halogen atoms; R', R'' = H, alkyl, cycloalkyl, etc.], useful in the treatment of viral infections, more particularly, for the treatment of respiratory syncytial virus infection, were prepared. Thus, reacting I [W = O; R1 = (CH2)3NH2; R2 = cyclopropyl; R3-R6 = H; E = N; A, B, D = CH] (preparation given) with N-chloroacetylucrethane in the presence of Na2CO3 in MeCN afforded 39% II.TFA. The compds. I showed antiviral activity against RSV with EC50's between 50 μ M and 0.001 μ M vs. Ribavirin with an EC50 of 3 μ M.

ACCESSION NUMBER: 2001:923615 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:37623

TITLE: Preparation of imidazopyridine and imidazopyrimidine

antiviral agents

INVENTOR(S): Yu, Kuo-Long; Civiello, Rita L.; Combrink,

Keith D.; Gulgeze, Hatice Belgin; Sin, Ny; Wang,
 Xiangdong; Meanwell, Nicholas A.; Venables, Brian Lee
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 196 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2001095910	A1	20011220	WO 2001-US14775	
20010508 <--				
CH, CN, GH, GM, LR, LS, PT, RO, UZ, VN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, YU, ZA, ZW			
CH, CY, TR, BF,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


FILE 'REGISTRY' ENTERED AT 16:00:51 ON 07 DEC 2009
 E 114054-02-9/RN
 E 1140054-02-9/RN
 SET EXPAND CONTINUOUS
 L7 1 S E3
 L8 1 S E4
 L9 1 S E6
 L10 1 S E7
 E 1140054-36-9/RN
 L11 1 S E15
 E 317589-57-4/RN
 L12 1 S E27
 E 380602-42-6/RN
 L13 1 S E39
 L14 1 S E42
 L15 1 S E43
 L16 1 S E44
 E 380602-53-9/RN
 L17 1 S E51
 E 380603-02-1/RN
 L18 1 S E63

L19 1 S E70
L20 1 S E71
L21 1 S E72
E 380603-12-3/RN
L22 1 S E75
E 380604-00-2/RN
L23 1 S E87
L24 1 S E89
L25 1 S E95
E 380604-10-4/RN
L26 1 S E99
L27 1 S E104
L28 1 S E108
E 380604-21-7/RN
L29 1 S E111
E 406940-52-1/RN
L30 1 S E123

FILE 'REGISTRY' ENTERED AT 16:13:41 ON 07 DEC 2009
L31 STRUCTURE uploaded

L31 STRUCTURE uploaded

=> d l31
L31 HAS NO ANSWERS
L31 STR



G1 C,S
G2 Cy,Ak

L32 50 S L31 SSS SAM
L33 1481 S L31 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:15:22 ON 07 DEC 2009
L34 511 S L33
L35 424 S L34 AND (PY<2004 OR AY<2004 OR PRY<2004)
L36 2 S L35 AND (SYNCYTIAL?)
L37 4 S L35 AND (VIRAL?)
L38 4 S L37 AND (PY<2004 OR AY<2004 OR PRY<2004)
L39 2 S L38 NOT L36


FILE 'REGISTRY' ENTERED AT 16:18:37 ON 07 DEC 2009
E 304681-21-8/RN

L40 1 S E135
L41 1 S E136
L42 1 S E137
L43 1 S E140

FILE 'REGISTRY' ENTERED AT 16:21:36 ON 07 DEC 2009
L44 STRUCTURE UPLOADED

L44 STRUCTURE UPLOADED

=> d 144
L44 HAS NO ANSWERS
L44 STR



G1 Cy,Ak

L45 50 S L44 SSS SAM
L46 1901 S L44 SSS FULL


FILE 'HCAPLUS' ENTERED AT 16:22:34 ON 07 DEC 2009
L47 409 S L46
L48 341 S L47 AND (PY<2004 OR AY<2004 OR PRY<2004)
L49 1 S L48 AND (SYNCYTIAL?)
L50 2 S L48 AND (VIRAL?)
L51 1 S L50 NOT L49
L52 3 S L48 AND (RESPIRATORY)
L53 2 S L52 NOT L49

L53 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI A phase 1 study of the cholecystokinin (CCK) B antagonist L-
365,260 in

AB human subjects taking morphine for intractable non-cancer pain
To investigate the safety and tolerability of L-365,260 in human
subjects taking morphine for intractable pain. An open label
study of nine adult subjects. Two doses of L-365,260 were
administered to all subjects separated by a 4 h interval (three
received 10 mg, three 30 mg and three 60 mg). Hemodynamic and
respiratory variables were recorded from immediately prior to
first drug administration to T+600 min. In addition, continuous
ECG monitoring and serial 12 lead ECGs were recorded along with
pain and side effect measurements. No major side effects were
observed. L-365,260 was well tolerated. No abnormalities in blood
pressure, heart rate, respiratory rate or ECG measurements were

recorded. Minor side effects were observed L-365,260 can be safely administered at the doses investigated to human subjects receiving morphine for intractable pain.
 ACCESSION NUMBER: 2002:807031 HCPLUS Full-text
 DOCUMENT NUMBER: 138:348601
 TITLE: A phase 1 study of the cholecystokinin (CCK) B antagonist L-365,260 in human subjects taking morphine
 for intractable non-cancer pain
 AUTHOR(S): McCleane, Gary J.
 CORPORATE SOURCE: Rampark Pain Centre, Lurgan, BT66 7JH, UK
 SOURCE: Neuroscience Letters (2002), 332(3), 210-212
 CODEN: NELEBD; ISSN: 0304-3940
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CC 1-11 (Pharmacology)
 IT 118101-09-0, L-365260
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effect of L-365260 in human subjects with intractable non-cancer pain)
 OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2009 ACS on STN
 TI Inhibitors of interleukin-1 β converting enzyme
 GI



AB The present invention relates to novel classes of compds. I [RC:CR is an optionally substituted aryl or heteroaryl ring; R1 = aryl, heteroaryl, alkylaryl, alkylheteroaryl; R2 = bond, CO, COCO, SO2, OCO, NHCO, NHSO2, NHOCOCO, CH:CHCO, OCH2CO, NHCH2CO, etc.; R3 = aryl, heteroaryl, cycloalkyl, alkyl, dialkylamino; Y = R5CO(CH2)mCH2CH(COR6) or related lactones or semicarbazones, where R5 = OH, alkoxy, NHOH, etc.; R6 = H, HOCH2, aroyloxymethyl, etc.; m = 0 or 1] which were prepared as inhibitors of interleukin-1 β converting enzyme. (ICE). Thus, (3S)-3-[3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H-1,4-benzodiazepin-1-acetylamino]-4-oxobutyric acid, prepared from 3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H-

1,4- benzodiazepin-1-acetic acid and (3S)-3-(1-fluorenylmethoxycarbonylamino)-4- oxobutyric acid tert-Bu ester semicarbazone, showed ICE inhibition constant $K_i = 650$ nM and IC₅₀ = 20,000 nM.

ACCESSION NUMBER: 1998:394349 HCPLUS [Full-text](#)
DOCUMENT NUMBER: 129:54608
ORIGINAL REFERENCE NO.: 129:11385a,11388a
TITLE: Inhibitors of interleukin-1 β converting enzyme
INVENTOR(S): Golec, Julian M. C.; Lauffer, David J.; Livingston,
David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA; Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.
SOURCE: PCT Int. Appl., 135 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 9824805 19971205 <--	A1	19980611	WO 1997-US22289	
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, KP, KR, NO, NZ, UA, UG,	DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, US, UZ, VN, YU, ZW			
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, CM, GA,	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, GN, ML, MR, NE, SN, TD, TG			
CA 2274249 19971205 <--	A1	19980611	CA 1997-2274249	
AU 9858960 19971205 <--	A	19980629	AU 1998-58960	
EP 944645 19971205 <--	A1	19990929	EP 1997-954531	
EP 944645 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,	B1	20050309		

MC, PT, IE, FI
 JP 2001505883 T 20010508 JP 1998-525818
 19971205 <--
 JP 4274584 B2 20090610
 AT 290545 T 20050315 AT 1997-954531
 19971205 <--
 ES 2239788 T3 20051001 ES 1997-954531
 19971205 <--
 US 6329365 B1 20011211 US 1999-326495
 19990604 <--
 US 20030069228 A1 20030410 US 2001-35850
 20011023 <--
 US 6573259 B2 20030603
 US 20040048855 A1 20040311 US 2003-424576
 20030425 <--
 US 6974809 B2 20051213
PRIORITY APPLN. INFO.: US 1996-32792P P
 19961206 <-- US 1997-42660P P
 19970404 <-- US 1997-53001P P
 19970626 <-- WO 1997-US22289 W
 19971205 <-- US 1999-326495 A3
 19990604 <-- US 2001-35850 A3
 20011023 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 129:54608
 IC ICM C07K005-023
 ICS A61K038-06
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 28, 63
 IT Respiratory distress syndrome
 (newborn; inhibitors of interleukin-1 β converting enzyme)
 IT 172968-04-6P 208758-94-5P 208758-95-6P 208758-96-7P
 208758-97-8P
 208758-98-9P 208758-99-0P 208759-00-6P 208759-01-7P
 208759-02-8P
 208759-03-9P 208759-04-0P 208759-05-1P 208759-06-2P
 208759-07-3P
 208759-09-5P 208759-11-9P 208759-13-1P 208759-15-3P
 208759-17-5P 208759-19-7P 208759-21-1P 208759-24-4P
 208759-26-6P
 208759-28-8P 208759-30-2P 208759-32-4P 208759-38-0P
 208759-39-1P
 208759-40-4P 208759-41-5P 208759-42-6P 208759-43-7P
 208759-44-8P
 208759-45-9P 208759-46-0P 208759-47-1P 208759-48-2P
 208759-49-3P
 208759-50-6P 208759-51-7P 208759-52-8P 208759-53-9P
 208759-54-0P
 208759-55-1P 208759-56-2P 208759-57-3P 208759-58-4P
 208759-59-5P
 RL: BAC (Biological activity or effector, except adverse); BS


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOl (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of interleukin-1 β converting enzyme)

L55 STRUCTURE UPLOADED

=> d 155

L55 HAS NO ANSWERS

L55 STR



FILE 'REGISTRY' ENTERED AT 16:25:25 ON 07 DEC 2009
E 208759-11-9/RN

L54 1 S E147

FILE 'REGISTRY' ENTERED AT 16:27:13 ON 07 DEC 2009
L55 STRUCTURE UPLOADED
L56 2 S L55 SSS SAM
L57 7 S L55 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:28:08 ON 07 DEC 2009
L58 10 S L57
L59 9 S L58 AND (PY<2004 OR AY<2004 OR PRY<2004)
L60 1 S L59 AND VIRAL?
L61 1 S L60 AND RESPIRATORY

L61 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Inhibitors of interleukin-1 β converting enzyme
ACCESSION NUMBER: 1998:394349 HCAPLUS Full-text
DOCUMENT NUMBER: 129:54608
ORIGINAL REFERENCE NO.: 129:11385a,11388a
TITLE: Inhibitors of interleukin-1 β converting enzyme
INVENTOR(S): Golec, Julian M. C.; Lauffer, David J.;
Livingston, David J.; Mullican, Michael D.; Murcko, Mark
A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker,
Marion W.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA;
Golec, Julian M. C.; Lauffer, David J.; Livingston,
David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce,

Philip
 W.
 SOURCE: PCT Int. Appl., 135 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824805 19971205 <--	A1	19980611	WO 1997-US22289	
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG CA 2274249 19971205 <--			CA 1997-2274249	
AU 9858960 19971205 <--	A	19980629	AU 1998-58960	
EP 944645 19971205 <--	A1	19990929	EP 1997-954531	
EP 944645 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI JP 2001505883 19971205 <--	B1	20050309		
JP 4274584 AT 290545 19971205 <--	T	20010508	JP 1998-525818	
ES 2239788 19971205 <--	B2	20090610		
US 6329365 19990604 <--	T	20050315	AT 1997-954531	
US 20030069228 20011023 <--	T3	20051001	ES 1997-954531	
US 6573259 US 20040048855 20030425 <--	B1	20011211	US 1999-326495	
US 6974809 19961206 <--	A1	20030410	US 2001-35850	
PRIORITY APPLN. INFO.: US 2003069228 19961206 <--	B2	20030603		
	A1	20040311	US 2003-424576	
	B2	20051213		
			US 1996-32792P	P
			US 1997-42660P	P

19970404 <-- US 1997-53001P P
 19970626 <-- WO 1997-US22289 W
 19971205 <-- US 1999-326495 A3
 19990604 <-- US 2001-35850 A3
 20011023 <--
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 129:54608
 IC ICM C07K005-023
 ICS A61K038-06
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 28, 63
 IT Respiratory distress syndrome
 (newborn; inhibitors of interleukin-1 β converting enzyme)
 IT Hepatitis
 (viral, chronic active; inhibitors of interleukin-1 β
 converting enzyme)
 IT 172968-04-6P 208758-94-5P 208758-95-6P 208758-96-7P
 208758-97-8P 208758-98-9P 208758-99-0P 208759-00-6P 208759-01-7P
 208759-02-8P 208759-03-9P 208759-04-0P 208759-05-1P 208759-06-2P
 208759-07-3P 208759-09-5P 208759-11-9P 208759-13-1P 208759-15-3P
 208759-17-5P 208759-19-7P 208759-21-1P 208759-24-4P
 208759-26-6P 208759-28-8P 208759-30-2P 208759-32-4P 208759-38-0P
 208759-39-1P 208759-40-4P 208759-41-5P 208759-42-6P 208759-43-7P
 208759-44-8P 208759-45-9P 208759-46-0P 208759-47-1P 208759-48-2P
 208759-49-3P 208759-50-6P 208759-51-7P 208759-52-8P 208759-53-9P
 208759-54-0P 208759-55-1P 208759-56-2P 208759-57-3P 208759-58-4P
 208759-59-5P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibitors of interleukin-1 β converting enzyme)

L1	STRUCTURE UPLOADED
L2	3 S L1 SSS SAM
L3	67 S L1 SSS FULL
L4	STRUCTURE UPLOADED
L5	0 S L4 SSS SAM
L6	6 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:43:23 ON 08 DEC 2009

L7 2 S L6
L8 10 S L3
L9 9 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10 0 S L9 AND (VIRAL OR VIRUS?)
L11 0 S L9 AND (SYNCYTIAL?)
L12 0 S L9 AND RESPIRATORY
L13 2 S L9 AND ?FLU?

FILE 'REGISTRY' ENTERED AT 12:51:21 ON 08 DEC 2009


L14 STRUCTURE uploaded
L15 0 S L14 SSS SAM
L16 0 S L14 SSS FULL
L17 STRUCTURE uploaded

L17 STRUCTURE uploaded

=> d 117

L17 HAS NO ANSWERS

L17 STR



L18 0 S L17 SSS SAM
L19 0 S L17 SSS FULL

L1 1 S US 20070185096/PN


FILE 'REGISTRY' ENTERED AT 18:10:50 ON 16 DEC 2009
L2 1 S 317846-22-3/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY
L3 0 S L1 AND 'BIS(5-AMIDINO-2-BENZIMIDAZOLYL)-METHANE'
L4 1 S 'BIS(5-AMIDINO-2-BENZIMIDAZOLYL)-METHANE'

FILE 'HCAPLUS' ENTERED AT 18:13:47 ON 16 DEC 2009


FILE 'REGISTRY' ENTERED AT 18:14:05 ON 16 DEC 2009
E 74733-75-8/RN

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 74733-75-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Benzimidazole-6-carboximidamide, 2,2'-methylenebis- (CA INDEX
 NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis- (9CI)
 OTHER NAMES:
 CN APD 1
 CN BABIM
 CN Bis(5-Amidino-2-benzimidazolyl)methane
 MF C17 H16 N8
 CI COM
 LC STN Files: ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO,
 CA,
 CAPLUS, EMBASE, IMSRESEARCH, MEDLINE, PHAR, PROUSDDR, TOXCENTER,
 USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)



SET EXPAND CONTINUOUS
 L5 1 S E3
 FILE 'HCAPLUS' ENTERED AT 18:14:37 ON 16 DEC 2009
 L6 54 S LS
 L7 7 S L6 AND (SYNCYTIAL?)
 L8 6 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
 L8 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Inhibition of respiratory syncytial virus-induced cell fusion by
 amidino compounds
 GI



AB A number of aromatic mono- and bis-amidines I (R = H or C(NH)NH₂, X = alkane-1, ω -diyl or 2-hydroxybutane-1,4-diyl), II (n = 1 or 2), and III (X = CH or N; XI = O, NH, NMe, or NCH₂C₆H₄C(NH)NH-4) capable of blocking cell fusion induced by respiratory syncytial (RS) virus are described. I (R = H, X = hexane-1,6-diyl or octane-1,8-diyl) were synthesized. The most powerful of the compds., II [74733-75-8] (n = 1), completely suppressed syncytium formation at a concentration of 1 μ M. Inhibition occurs in RS virus-infected Hep-2 cells as well as CV-1 cells. II (n = 1) also caused a significant retardation of RS virus penetration, but did not interfere with adsorption. Addition of the amidines after the penetration of RS virus does not affect single cycle yields. Structure-activity relations are discussed. The compds. may be used in the prophylactic control of RS virus in man.

ACCESSION NUMBER: 1982:417115 HCAPLUS [Full-text](#)
DOCUMENT NUMBER: 97:17115
ORIGINAL REFERENCE NO.: 97:2905h, 2906a
TITLE: Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
INVENTOR(S): Tidwell, Richard R.; Dubovi, Edward J.; Geratz, Joachim D.
PATENT ASSIGNEE(S): Research Triangle Institute, USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4324794	A	19820413	US 1980-181341	
19800826 <--				
US 4397863	A	19830809	US 1982-366652	
19820408 <--				
US 4619942	A	19861028	US 1983-521084	
19830808 <--				
PRIORITY APPLN. INFO.:			US 1980-181341	A3
19800826 <--			US 1982-366652	A3
19820408 <--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 97:17115

IC A61K031-415; A61K031-155; A61K031-40

INCL 424273000B

CC 1-5 (Pharmacology)

IT 100-33-4 618-39-3 67834-00-8 71889-74-2 71889-75-3

71889-77-5

71892-45-0 74733-75-8 75846-15-0 77838-88-1 77838-93-8

RL: BIOL (Biological study)

(virus-induced cell fusion inhibition by, structure in relation to)